Product Code: GMDHC1996TDB
Summary
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B). The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 4 and 2 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Ear Nose Throat Disorders, Immunology, Infectious Disease, Metabolic Disorders and Respiratory which include indications Breast Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Neuroblastoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Astrocytoma, Colon Cancer, Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hearing Disorders, Laryngeal Cancer, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Thymic Carcinoma, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
Furthermore, this report also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Overview
- Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
- Adastra Pharmaceuticals Inc
- Apollo Therapeutics LLC
- Astex Pharmaceuticals Inc
- Cyclacel Pharmaceuticals Inc
- G1 Therapeutics Inc
- Neosome Life Sciences LLC
- Pfizer Inc
- Prous Institute for Biomedical Research SA
- Rizen (Suzhou) Biosciences Co Ltd
- Tiziana Life Sciences Plc
- Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Drug Profiles
- AT-7519 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CCT-68127 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CYC-065 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- JRP-890 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- JS-104 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- kenpaullone - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- milciclib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NEOS-518 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PF-06873600 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- sapacitabine + seliciclib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- seliciclib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit CDK2 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- zotiraciclib citrate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Dormant Products
- Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Discontinued Products
- Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
- Featured News & Press Releases
- Dec 09, 2019: Cyclacel's CYC065 and Venetoclax demonstrate therapeutic potential and anticancer activity in acute myeloid and chronic lymphocytic leukemias
- Nov 06, 2019: Cyclacel Pharmaceuticals announces multiple clinical abstracts on CYC065 selected for presentation at the ASH 2019 Annual Meeting
- Sep 09, 2019: Cyclacel Pharmaceuticals announces first patient treated with oral CYC065 in a phase 1 study in patients with advanced solid tumors
- Sep 04, 2019: Tiziana Life Sciences -phase 2a clinical data
- Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference
- Jul 24, 2019: Tiziana reveals positive results for Milciclib in liver cancer trial
- Jul 22, 2019: Tiziana reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
- Jun 03, 2019: Adastra Pharmaceuticals announces positive interim data from Phase 1b clinical trial of zotiraciclib in the treatment of recurrent malignant gliomas
- May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019
- Apr 24, 2019: Tiziana reports encouraging interim clinical data from an ongoing phase 2a trial with milciclib in advanced liver cancer patients
- Mar 25, 2019: Cyclacel: Publication identifies cyclin e as key resistance pathway to Breast Cancer treated by CDK4/6 inhibitors and thereby amenable to treatment by CYC065 CDK2/9 inhibitor
- Mar 05, 2019: Cyclacel announces CYC065 abstract presentation at the American Association for Cancer Research Annual Meeting 2019
- Dec 03, 2018: Tiziana Completes patient enrollment in a phase 2a trial to evaluate tolerability and anti-tumor activity of Milciclib in hepatocellular carcinoma (HCC)
- Oct 16, 2018: Tiziana Life Sciences presents data from animal studies demonstrating the potential synergistic activity of Milciclib with tyrosine kinase inhibitors to treat Hepatocellular Carcinoma (HCC) at the American Association for the Study of Liver Diseases (AASLD)
- Jun 14, 2018: Lees Pharmaceutical Holdings: Update on An Investigational Oncology Product
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H2 2019
- Number of Products under Development by Therapy Areas, H2 2019
- Number of Products under Development by Indications, H2 2019
- Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
- Number of Products under Development by Companies, H2 2019
- Products under Development by Companies, H2 2019
- Products under Development by Companies, H2 2019 (Contd..1), H2 2019
- Products under Development by Companies, H2 2019 (Contd..2), H2 2019
- Number of Products under Investigation by Universities/Institutes, H2 2019
- Products under Investigation by Universities/Institutes, H2 2019
- Number of Products by Stage and Mechanism of Actions, H2 2019
- Number of Products by Stage and Route of Administration, H2 2019
- Number of Products by Stage and Molecule Type, H2 2019
- Pipeline by Adastra Pharmaceuticals Inc, H2 2019
- Pipeline by Apollo Therapeutics LLC, H2 2019
- Pipeline by Astex Pharmaceuticals Inc, H2 2019
- Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
- Pipeline by G1 Therapeutics Inc, H2 2019
- Pipeline by Neosome Life Sciences LLC, H2 2019
- Pipeline by Pfizer Inc, H2 2019
- Pipeline by Prous Institute for Biomedical Research SA, H2 2019
- Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2019
- Pipeline by Tiziana Life Sciences Plc, H2 2019
- Dormant Products, H2 2019
- Dormant Products, H2 2019 (Contd..1), H2 2019
- Dormant Products, H2 2019 (Contd..2), H2 2019
- Discontinued Products, H2 2019
List of Figures
- Number of Products under Development by Stage of Development, H2 2019
- Number of Products under Development by Therapy Areas, H2 2019
- Number of Products under Development by Top 10 Indications, H2 2019
- Number of Products by Stage and Mechanism of Actions, H2 2019
- Number of Products by Routes of Administration, H2 2019
- Number of Products by Stage and Routes of Administration, H2 2019
- Number of Products by Stage and Molecule Type, H2 2019
